This variant has been linked to the altered activity of the ABCB1 multidrug resistance gene [16], pharmacoresistance in temporal lobe epilepsy [17], the risk for chronic myeloid leukemia, the atorvastatin treatment response, steroid-resistant nephrotic syndrome, prognosis in esophageal squamous cell carcinoma patients treated with a taxane [18], and clinical predictors of ondansetron failure in a diverse pediatric oncology population [19]. Here, ABCB1 is linked to temporal lobe epilepsy.